Algernon’s Investigational Anti-fibrotic, NP-120, Surpasses Esbriet, Ofev in Reducing Scarred Tissue in IPF Mice

Algernon’s Investigational Anti-fibrotic, NP-120, Surpasses Esbriet, Ofev in Reducing Scarred Tissue in IPF Mice

NP-120, Algernon Pharmaceuticals‘ repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF), surpassed two other globally approved therapies — Genentech‘s Esbriet (pirfenidone) and Boehringer Ingelheim‘s Ofev (nintedanib) — in reducing lung tissue scarring (fibrosis) in a mouse model of IPF. Current guidelines…

Writing Your Own Respiratory Protocol

Life with a fatal lung disease like idiopathic pulmonary fibrosis (IPF) is very unpredictable. I thrive in routine, familiarity, and structure, so I have difficulty accepting that this disease can force instant changes. I’m still working on learning to let go of what I cannot control, like an…